Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
Statement: GSK supports GOLD committee’s efforts to further personalise COPD management
Welcoming the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy.
Read more -
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV
BRIGHTE study highlights ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV, including those heavily-treated and failing on current a...
Read more -
GSK delivers Q3 sales of £8.1 billion, +3% AER, +6% CER
Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER
Read more -
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
FLAIR study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen of cabotegravir and rilpivirine compared to a daily,...
Read more -
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen
LATTE-2 study shows high rates of virologic response and long-term durability with the long-acting, injectable, two-drug regimen over 160 weeks
Read more -
GSK announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease
Second of three pivotal studies intended to support regulatory filing in Japan in 2019
Read more -
GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Marked patient benefit observed in phase II study supports further clinical development of GSK3196165 for RA.
Read more -
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
Read more -
GSK updates policy for working with healthcare professionals
We are updating our policy on working with healthcare professionals (HCPs).
Read more -
Positive results from Harmony Outcomes study of albiglutide published in The Lancet
GSK and the Duke Clinical Research Institute (DCRI) today announced publication of positive results from the Harmony Outcomes study which assessed the cardiovascular (CV) safety...
Read more -
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions
Read more -
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in diseases of the developing world.
Read more -
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone fu...
Read more -
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria
Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
Read more -
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of doluteg...
Read more -
GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
GlaxoSmithKline plc (GSK) will profile the growing evidence base that supports its broad respiratory medicines portfolio at the European Respiratory Society (ERS) congress in Pa...
Read more -
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
Nucala demonstrated greater reduction in exacerbations and improved asthma control.
Read more -
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc (LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab as an add-on treatment to inhaled c...
Read more -
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
Read more -
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
ATLAS study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen of cabotegravir and rilpivirine compared to a standa...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
